CN111214538A - Composition for preventing and treating lower urinary tract diseases of dogs and cats, chewable tablets thereof and preparation method - Google Patents

Abstract

The invention discloses a composition for preventing and treating lower urinary tract diseases of dogs and cats, a chewable tablet and a preparation method thereof, wherein the chewable tablet comprises the following components in parts by mass: 30-40% of active ingredients; 1.8 to 2.4 percent of adhesive; 10-15% of a humectant; 5-7% of an emulsifier; 8-10% of flavoring agent; 3-4% of antioxidant; 0.5-1% of preservative; 5-7% of a disintegrating agent; 0.1-1% of lubricant; the active ingredients comprise quercus salicifolius extract, shrimp and crab shell extract, cranberry extract and desmodium extract, the composition has comprehensive effects and good palatability, and can be used for a long time in the disease period of dogs and cats or after disease rehabilitation, so the composition is suitable for popularization.

Description

Composition for preventing and treating lower urinary tract diseases of dogs and cats, chewable tablets thereof and preparation method

Technical Field

The invention relates to the field of pet medical treatment, in particular to a composition for preventing and treating lower urinary tract diseases of dogs and cats, a chewable tablet thereof and a preparation method thereof.

Background

The diseases of the lower urinary tract of dogs and cats are descriptions of various diseases occurring in the lower urinary tract of dogs and cats, but do not refer to a single disease, the disease is also called as urinary system syndrome of dogs and cats, and the main clinical symptoms are urinary frequency, dysuria, urinary pain, blood in urine, abnormal urination behavior and the like. The disease is caused by the stimulation of bladder and urethral calculus, crystallization, embolism and the like, and the inflammation of the mucous membrane of the bladder and the urethra is caused. The occurrence rate is mostly 1-6 years old, and male and female cats occur, and the incidence rate of castrated male cats and long-haired cats (especially Persian cats) is the highest. Urethral blockage is more common in males, and cystitis and urethritis are more frequent in females.

About 40% of affected dogs are cystitis and about 20% are uroliths; about 60% of diseased cats are primary cystitis, about 20% are uroliths, 10% originate from urethral emboli, 8% from urinary tract infections, 3% from unknown factors. In some severe cases, the symptoms of the disease are relieved by themselves after 5 to 10 days, but the disease has high recurrence rate and can recur irregularly, and about 30 to 70 percent of dogs and cats suffering from the lower urinary tract disease can recur the disease. The disease is easy to relapse, is the reason that the lower urinary tract diseases of dogs and cats are difficult to radically cure, and is a great clinical problem which troubles pet doctors and pet owners.

Urolithiasis is a multifactorial disease caused by metabolic abnormalities that affects the composition of body fluids and urine. Since about 80% of stones are composed of calcium oxalate and calcium phosphate, elevated levels of calcium oxalate and phosphate in urine play an important role in the formation and recurrence of stones. Since the rate of stone recurrence is quite high, with 50% recurrence within 10 years and 75% recurrence within 15 years without any treatment, dietary improvement appears to be important for reducing the risk of urolithiasis. However, no drug treatment for preventing the formation of calculus is available at present.

Spontaneous cystitis has no specific etiology and is the most common lower urinary tract disease of cats aged 1-10 years, a layer of glycosaminoglycan (GAG) chain is arranged on the inner wall of the bladder of dogs and cats, the normal bladder is protected by the GAG chain, and when the GAG chain is damaged, the inner wall of the bladder is stimulated, so that the cystitis is caused; the bladder tunica interna is broken and falls off, and is especially the culprit of urethral blockage; and at the same time, it is a common clinical approach to repair the GAG chain.

In the prior art, the problems of poor palatability, single effect and the like only aiming at certain symptoms of urinary tract diseases exist.

Accordingly, the prior art is subject to further development and advancement.

Disclosure of Invention

Aiming at the technical problems, the embodiment of the invention provides a composition for preventing and treating lower urinary tract diseases of dogs and cats, a chewable tablet thereof and a preparation method thereof.

The technical scheme of the invention is as follows:

the composition for preventing and treating the lower urinary tract diseases of dogs and cats comprises the following components in parts by mass:

30-40% of active ingredients;

1.8 to 2.4 percent of adhesive;

10-15% of a humectant;

5-7% of an emulsifier;

8-10% of flavoring agent;

3-4% of antioxidant;

0.5-1% of preservative;

5-7% of a disintegrating agent;

0.1-1% of lubricant;

the balance of filler, and the active ingredients comprise Quercus salicina extract, shrimp and crab shell extract, cranberry extract and herba Lysimachiae Christinae extract.

Preferably, the addition ratio of the quercus salicifolius extract, the shrimp and crab shell extract, the cranberry extract and the desmodium extract is 4:4:1: 1.

Preferably, the quercus salicifolius extract is a gravelly willow leaf extract, the main effective component is tannic acid, and the content of the tannic acid is 30% -40%; the shrimp and crab shell extract is prepared by deproteinizing and demineralizing shrimp and crab shells and performing enzymatic hydrolysis, wherein the main active ingredient is N-acetylglucosamine, and the content of the N-acetylglucosamine is 85-88%; the cranberry extract contains procyanidin as an active ingredient, and the content of procyanidin is 50-60%; the main effective components of the herba Lysimachiae Christinae extract are flavone and tannic acid, wherein flavone content is 5-8%, and tannic acid content is 5-6%.

Preferably, the binder is one of starch, hydroxypropyl methylcellulose and povidone; the humectant consists of glycerol and medium-chain triglyceride, and the addition ratio of the glycerol to the medium-chain triglyceride is 2:3 or 1: 2; the emulsifier consists of phospholipid and polyethylene glycol ricinoleate, and the addition ratio of the phospholipid to the polyethylene glycol ricinoleate is 1: 1; the flavoring agent is one of polypeptide chicken powder, polypeptide pork powder, polypeptide beef powder and polypeptide tuna powder; the antioxidant is any two of licorice antioxidant, dilauryl thiodipropionate, ethoxyquinoline, butyl hydroxyanisole, tea polyphenol and vitamin E; the preservative is one of nisin, epsilon-polylysine hydrochloride and sodium dehydroacetate; the disintegrant is sodium carboxymethyl starch or crospovidone; the lubricant is magnesium stearate; the filler consists of sorbitol and sucrose, and the adding ratio of the sorbitol to the sucrose is 1:1 or 2: 1.

A preparation method of chewable tablets for preventing and treating diseases of lower urinary tract of dogs and cats comprises the following specific steps:

step 1, preparing a binder into a solution A with the concentration of 3-4% by using hot water at 100 ℃ which is 60% of the mass of a finished product to be prepared, and cooling to room temperature for later use;

step 2, pouring the humectant and the emulsifier into the solution A in sequence and stirring uniformly to prepare a solution B;

step 3, uniformly mixing the active ingredients, the flavoring agent, the antioxidant, the preservative, the disintegrating agent and the filler, and sieving the mixture by a 40-mesh sieve to obtain a solid powder mixture C;

step 4, adding the solution B into the solid powder mixture C for multiple times in a small amount to prepare wet particles, and grading the particles by using a 14-mesh screen of a swing type granulator;

step 5, putting the wet particles into a 40-DEG C oven for drying for 50-60 minutes to keep the moisture of the particles between 8-10%;

and 6, adding a lubricant into the granules prepared in the step 5, uniformly mixing, and then pressing and molding.

Advantageous effects

The invention provides a composition for preventing and treating lower urinary tract diseases of dogs and cats, a chewable tablet thereof and a preparation method thereof.

Drawings

FIG. 1 is a graph of the pH of urine over time for dogs with urolithiasis/cystitis using chewable tablets in accordance with an embodiment of the present invention;

FIG. 2 is a graph of the rate of urinary stone crystal improvement over time for dogs with urolithiasis/cystitis using chewable tablets in accordance with an embodiment of the present invention;

FIG. 3 is a graph of urine pH as a function of time for cats with urolithiasis/cystitis using a chewable tablet in accordance with an embodiment of the present invention;

FIG. 4 is a graph of the amount of uroliths in the urine of a cat suffering from urolithiasis/cystitis versus time using a chewable tablet in accordance with an embodiment of the present invention;

figure 5 is a graph of urine volume as a function of time for cats with urolithiasis/cystitis using a chewable tablet in accordance with an embodiment of the present invention.

Detailed Description

The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items. In addition, the technical features involved in the different embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.

The following are specific examples:

specific example 1:

a composition for preventing and treating lower urinary tract diseases of dogs and cats, chewable tablets and a preparation method thereof comprise the following components in parts by mass:

the preparation method comprises the following steps:

(1) preparing hydroxypropyl methyl cellulose into a solution A with the concentration of 3.33% by using hot water at 100 ℃ which is 60% of the mass of a finished product to be prepared, and cooling to room temperature for later use;

(2) sequentially pouring glycerol, medium-chain triglyceride, phospholipid and polyethylene glycol glycerol ricinoleate into the solution A and uniformly stirring to obtain a solution B;

(3) soaking 100g of freeze-dried Quercus salicina leaf in 1L of distilled water for 2 hours, centrifuging at a high speed (30000g) for 30 minutes, filtering by using a 0.4um filter, dissolving by using DMSO (dimethyl sulfoxide) after filtering to obtain a concentration of 50mg/ml, and concentrating by heating evaporation and freeze drying to obtain a Quercus salicina extract; shrimp and crab shell extracts were purchased from Shanghai Baomann Biotech Co., Ltd: n-acetylglucosamine; cranberry extract was purchased from sienna biotechnology limited: cranberry extract; the lysimachia extract was purchased from sienna yuze biotechnology limited: herba Lysimachiae Christinae extract.

(4) Mixing solid raw and auxiliary materials such as quercus salicifolius extract, shrimp and crab shell extract, cranberry extract, longhairy antenoron herb extract, polypeptide beef powder, dilauryl thiodipropionate, tea polyphenol, nisin, sodium carboxymethyl starch, sorbitol, sucrose and the like uniformly, and sieving by a 40-mesh sieve to obtain a solid powder mixture C;

(5) adding the solution B into the solid powder mixture C for multiple times in a small amount to prepare wet granules, and grading by using a 14-mesh screen of a swing type granulator;

(6) drying the wet granules in a 40-DEG oven for 60 minutes to reduce the water content of the granules to 8%;

(7) adding magnesium stearate into the granules obtained in step 5, mixing, and compressing with 15mm prototype punch on rotary tablet press to obtain tablet with weight of 1.58 + -0.3 g

Specific example 2:

a composition for preventing and treating lower urinary tract diseases of dogs and cats, chewable tablets and a preparation method thereof comprise the following components in parts by mass:

the preparation method comprises the following steps:

(1) preparing starch into 3% solution A with 60% hot water of 100 deg.C, and cooling to room temperature;

(2) sequentially pouring glycerol, medium-chain triglyceride, phospholipid and polyethylene glycol glycerol ricinoleate into the solution A and uniformly stirring to obtain a solution B;

(3) soaking 100g of freeze-dried Quercus salicina leaf in 1L of distilled water for 2 hours, centrifuging at a high speed (30000g) for 30 minutes, filtering by using a 0.4um filter, dissolving by using DMSO (dimethyl sulfoxide) after filtering to obtain a concentration of 50mg/ml, and concentrating by heating evaporation and freeze drying to obtain a Quercus salicina extract; shrimp and crab shell extracts were purchased from Shanghai Baomann Biotech Co., Ltd: n-acetylglucosamine; cranberry extract was purchased from sienna biotechnology limited: cranberry extract; the lysimachia extract was purchased from sienna yuze biotechnology limited: herba Lysimachiae Christinae extract.

(4) Mixing solid raw and auxiliary materials such as quercus salicifolius extract, shrimp and crab shell extract, cranberry extract, longhairy antenoron herb extract, polypeptide beef powder, dilauryl thiodipropionate, tea polyphenol, nisin, sodium carboxymethyl starch, sorbitol, sucrose and the like uniformly, and sieving by a 40-mesh sieve to obtain a solid powder mixture C;

(5) adding the solution B into the solid powder mixture C for multiple times in a small amount to prepare wet granules, and grading by using a 14-mesh screen of a swing type granulator;

(6) drying the wet granules in a 40-DEG oven for 60 minutes to reduce the water content of the granules to 8%;

(7) adding magnesium stearate into the granules obtained in step 5, mixing, and compressing with 15mm prototype punch on rotary tablet press to obtain tablet with weight of 1.58 + -0.3 g

Specific example 3:

a composition for preventing and treating lower urinary tract diseases of dogs and cats, chewable tablets and a preparation method thereof comprise the following components in parts by mass:

the preparation method comprises the following steps:

(1) preparing polyvidone (PVP) K30 into 3.33% solution A with 60% hot water at 100 deg.C, and cooling to room temperature;

(2) sequentially pouring glycerol, medium-chain triglyceride, phospholipid and polyethylene glycol glycerol ricinoleate into the solution A and uniformly stirring to obtain a solution B;

(3) soaking 100g of freeze-dried Quercus salicina leaf in 1L of distilled water for 2 hours, centrifuging at a high speed (30000g) for 30 minutes, filtering by using a 0.4um filter, dissolving by using DMSO (dimethyl sulfoxide) after filtering to obtain a concentration of 50mg/ml, and concentrating by heating evaporation and freeze drying to obtain a Quercus salicina extract; shrimp and crab shell extracts were purchased from Shanghai Baomann Biotech Co., Ltd: n-acetylglucosamine; cranberry extract was purchased from sienna biotechnology limited: cranberry extract; the lysimachia extract was purchased from sienna yuze biotechnology limited: herba Lysimachiae Christinae extract.

(4) Mixing solid raw and auxiliary materials such as quercus salicifolius extract, shrimp and crab shell extract, cranberry extract, longhairy antenoron herb extract, polypeptide beef powder, dilauryl thiodipropionate, tea polyphenol, nisin, sodium carboxymethyl starch, sorbitol, sucrose and the like uniformly, and sieving by a 40-mesh sieve to obtain a solid powder mixture C;

(5) adding the solution B into the solid powder mixture C for multiple times in a small amount to prepare wet granules, and grading by using a 14-mesh screen of a swing type granulator;

(6) drying the wet granules in a 40-DEG oven for 60 minutes to reduce the water content of the granules to 8%;

(7) adding magnesium stearate into the granules obtained in step 5, mixing, and compressing with 15mm prototype punch on rotary tablet press to obtain tablet with weight of 1.58 + -0.3 g

Specific example 4

A composition for preventing and treating lower urinary tract diseases of dogs and cats, chewable tablets and a preparation method thereof comprise the following components in parts by mass:

the preparation method comprises the following steps:

(1) preparing hydroxypropyl methylcellulose into a solution A with the concentration of 4% by using 60% hot water at 100 ℃, and cooling to room temperature for later use;

(2) sequentially pouring glycerol, medium-chain triglyceride, phospholipid and polyethylene glycol glycerol ricinoleate into the solution A and uniformly stirring to obtain a solution B;

(3) soaking 100g of freeze-dried Quercus salicina leaf in 1L of distilled water for 2 hours, centrifuging at a high speed (30000g) for 30 minutes, filtering by using a 0.4um filter, dissolving by using DMSO (dimethyl sulfoxide) after filtering to obtain a concentration of 50mg/ml, and concentrating by heating evaporation and freeze drying to obtain a Quercus salicina extract; shrimp and crab shell extracts were purchased from Shanghai Baomann Biotech Co., Ltd: n-acetylglucosamine; cranberry extract was purchased from sienna biotechnology limited: cranberry extract; the lysimachia extract was purchased from sienna yuze biotechnology limited: herba Lysimachiae Christinae extract.

(4) Mixing solid raw and auxiliary materials such as quercus salicifolius extract, shrimp and crab shell extract, cranberry extract, longhairy antenoron herb extract, polypeptide beef powder, dilauryl thiodipropionate, tea polyphenol, nisin, sodium carboxymethyl starch, sorbitol, sucrose and the like uniformly, and sieving by a 40-mesh sieve to obtain a solid powder mixture C;

(5) adding the solution B into the solid powder mixture C for multiple times in a small amount to prepare wet granules, and grading by using a 14-mesh screen of a swing type granulator;

(6) drying the wet granules in a 40-DEG oven for 60 minutes to reduce the water content of the granules to 8%;

(7) adding magnesium stearate into the granules obtained in step 5, mixing, and compressing with 15mm prototype punch on rotary tablet press to obtain tablet with weight of 1.58 + -0.3 g

The stability test method of the above four embodiments: the soft chewable tablets of the four specific formulations of the examples were packaged in aluminum plastic (60 tablets per group) and left under accelerated conditions for 6 months (40 ℃ ± 2 ℃, relative humidity 75% ± 5%), and the stability of the soft chewable tablets was observed and examined, mainly according to the following four criteria: the appearance, moisture content, active ingredient, and average tablet weight are shown in tables 1, 2, 3, and 4:

table 1: stability testing of Soft chewable tablets of the formulation of specific example 1

Table 2: example 2 stability verification test of Soft chewable tablets of the formulation

Table 3: example 3 stability verification test of Soft chewable tablets of the formulation

Table 4: example 4 stability verification test of Soft chewable tablets of the formulation

And (3) test results: from the results shown in tables 1 to 4, the soft chewable tablets of the four formulations of specific example 1 to specific example 4 have stable quality under accelerated conditions, no significant difference from the indexes at the beginning of the test, stable appearance, no mildew and deterioration, and no significant changes in the indexes such as water content, ready-made ingredient content, average tablet weight, and the like.

The evaluation test of the invention on the clinical treatment effect of the canine urinary calculus/cystitis comprises the following steps:

test animals: 22 dogs with urolithiasis or cystitis;

the test method comprises the following steps: taking the chewable tablet prepared according to the formula in the specific example 1, and evaluating the improvement condition of a dog before and after using the chewable tablet prepared according to the formula in the specific example 1 for 30 days according to the dosage of 1 tablet/5 kg of body weight twice a day;

evaluation indexes are as follows: 1. analyzing the pH value of the urine; 2. urinary stone crystal improvement rate;

and (3) test results:

1. as shown in fig. 1, the PH of the urolithiasis/cystitis (+) group (p <0.05) dropped significantly from day 0 to day 30;

2. as shown in FIG. 2, the urinary calculus/cystitis (-) group showed improvements of 56% (day 4), 67% (day 7), and 78% (day 14), respectively, and the group showed earlier improvements than the urinary calculus/cystitis (+) group.

The invention is used for evaluating the clinical treatment effect of the cat urinary calculus/cystitis and comprises the following steps:

test animals: 14 cats with urinary stones and 10 normal cats;

the test method comprises the following steps: taking the chewable tablet prepared according to the formula in the specific example 1, and evaluating the improvement condition of the cat before and after using the chewable tablet prepared according to the formula in the specific example 1 for 30 days according to the dosage of 1 tablet/5 kg of body weight twice a day;

evaluation indexes are as follows: 1. analyzing the pH value of urine; 2. analyzing the quantity of urinary calculi by using urine; urine volume at 3.24 hours;

and (3) test results:

1. as shown in FIG. 3, the pH in urine dropped significantly from 0-28 days;

2. as shown in fig. 4, the number of urinary stones decreased significantly from 0-28 days;

3. as shown in FIG. 5, the urine volume increased significantly from day 0 to day 21/28.

The medical history share for preventing recurrence of the feline idiopathic cystitis of the invention is as follows:

information of sick cats: persian cat, 2 years old, 2.5 kg, male dog. The disease is not castrated, the immunity is complete, the finished cat food is fed for a long time, two spontaneous cystitis histories are already existed in half a year, and the cat food is discharged from a hospital through conventional treatment and operation;

a relapse prevention treatment regimen: the soft chewable tablets of the formulation of example 2 were taken 2 times a day for 21 consecutive days, 1 tablet at a time, followed for one year;

the treatment effect is as follows: during the process of using the chewable tablet, the water drinking amount of the cat is greatly increased compared with the prior art, the urine volume is recovered to a normal level, and meanwhile, no cystitis symptom is seen in one year after the use, which shows that the product can well prevent the recurrence of the spontaneous cystitis.

The medical record sharing for preventing the recurrence of the canine urinary calculus of the invention comprises the following steps:

and (3) information of the sick dog: gibbells, 4 years old, 2.2 kg, male dogs, who have three episodes of struvite in the urethra within one year, were discharged from the hospital by conventional treatment surgery.

A relapse prevention treatment regimen: the soft chewable tablet of example 3 was taken 2 times a day for 20 consecutive days, 1 tablet each time, followed for two years.

The treatment effect is as follows: in the process of using the chewable tablet, the water drinking amount of a dog is obviously improved, the urine volume is increased, the pH value of urine is also greatly improved, and meanwhile, the dog does not generate urinary calculus within two years after the chewable tablet is used, which shows that the product can well prevent the recurrence of the urinary calculus of the dog.

It should be understood that the technical solutions and concepts of the present invention may be equally replaced or changed by those skilled in the art, and all such changes or substitutions should fall within the protection scope of the appended claims.

Claims (10)

1. The composition for preventing and treating the lower urinary tract diseases of dogs and cats is characterized by comprising the following components in parts by mass:

the balance being bulking agent, the active ingredients including Quercus salicina extract, shrimp and crab shell extract, cranberry extract and herba Lysimachiae Christinae extract.

2. The composition for preventing and treating diseases of the lower urinary tract of dogs and cats according to claim 1, wherein the active ingredient consists of quercus salicifolius extract, crayfish shell extract, cranberry extract and longhairy antenoron herb extract.

3. The composition for preventing and treating diseases of the lower urinary tract of dogs and cats according to claim 2, wherein the addition ratio of quercus salicifolius extract, crayfish shell extract, cranberry extract and desmodium extract is 4:4:1: 1.

4. The composition for preventing and treating diseases of the lower urinary tract of dogs and cats according to claim 2, wherein the Quercus salicifolia extract is a Quercus salicifolia leaf extract, the main effective component is tannic acid, and the content of tannic acid is 30% -40%; the shrimp and crab shell extract is prepared by deproteinizing and demineralizing shrimp and crab shells and performing enzymatic hydrolysis, wherein the main active ingredient is N-acetylglucosamine, and the content of the N-acetylglucosamine is 85-88%; the cranberry extract contains procyanidin as an active ingredient, and the content of procyanidin is 50-60%; the main effective components of the herba Lysimachiae Christinae extract are flavone and tannic acid, wherein flavone content is 5-8%, and tannic acid content is 5-6%.

5. The composition for preventing and treating diseases of the lower urinary tract of dogs and cats according to claim 1, wherein the binder is one of starch, hydroxypropyl methylcellulose, povidone; the humectant consists of glycerin and medium chain triglyceride; the emulsifier consists of phospholipid and polyethylene glycol glyceryl ricinoleate; the flavoring agent is one of polypeptide chicken powder, polypeptide pork powder, polypeptide beef powder and polypeptide tuna powder; the antioxidant is any two of licorice antioxidant, dilauryl thiodipropionate, ethoxyquinoline, butyl hydroxyanisole, tea polyphenol and vitamin E; the preservative is one of nisin, epsilon-polylysine hydrochloride and sodium dehydroacetate; the disintegrant is sodium carboxymethyl starch or crospovidone; the lubricant is magnesium stearate; the bulking agent consists of sorbitol and sucrose.

6. The composition for preventing and treating diseases of the lower urinary tract of dogs and cats according to claim 5, wherein the ratio of glycerol to medium chain triglyceride added in the humectant is 2:3 or 1: 2.

7. The composition for preventing and treating diseases of the lower urinary tract of dogs and cats according to claim 5, wherein the phospholipid and polyethylene glycol glyceryl ricinoleate are added in the ratio of 1:1 in the emulsifier.

8. The composition for preventing and treating diseases of the lower urinary tract of dogs and cats according to claim 5, wherein the adding ratio of sorbitol and sucrose in the filling agent is 1:1 or 2: 1.

9. A chewable tablet for preventing and treating diseases of lower urinary tract of dogs and cats, which is prepared from the composition of any one of claims 1-8.

10. A process for preparing chewable tablets for preventing and treating diseases of lower urinary tract of dogs and cats according to claim 9, which comprises the following steps:

step 1, preparing a binder into a solution A with the concentration of 3-4% by using hot water at 100 ℃ which is 60% of the mass of a finished product to be prepared, and cooling to room temperature for later use;

step 2, pouring the humectant and the emulsifier into the solution A in sequence and stirring uniformly to prepare a solution B;

step 3, uniformly mixing the active ingredients, the flavoring agent, the antioxidant, the preservative, the disintegrating agent and the filler, and sieving the mixture by a 40-mesh sieve to obtain a solid powder mixture C;

step 4, adding the solution B into the solid powder mixture C for multiple times in a small amount to prepare wet particles, and grading the particles by using a 14-mesh screen of a swing type granulator;

step 5, putting the wet particles into a 40-DEG C oven for drying for 50-60 minutes to keep the moisture of the particles between 8-10%;

and 6, adding a lubricant into the granules prepared in the step 5, uniformly mixing, and then pressing and molding.

Images